KR102581296B1 - 막 지질 코팅된 나노입자 및 사용 방법 - Google Patents

막 지질 코팅된 나노입자 및 사용 방법 Download PDF

Info

Publication number
KR102581296B1
KR102581296B1 KR1020197034265A KR20197034265A KR102581296B1 KR 102581296 B1 KR102581296 B1 KR 102581296B1 KR 1020197034265 A KR1020197034265 A KR 1020197034265A KR 20197034265 A KR20197034265 A KR 20197034265A KR 102581296 B1 KR102581296 B1 KR 102581296B1
Authority
KR
South Korea
Prior art keywords
virus
nanoparticles
membrane
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197034265A
Other languages
English (en)
Korean (ko)
Other versions
KR20190137906A (ko
Inventor
에디 요콘 청
Original Assignee
코스타 쎄라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코스타 쎄라퓨틱스 인크. filed Critical 코스타 쎄라퓨틱스 인크.
Publication of KR20190137906A publication Critical patent/KR20190137906A/ko
Application granted granted Critical
Publication of KR102581296B1 publication Critical patent/KR102581296B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
KR1020197034265A 2017-04-21 2018-04-21 막 지질 코팅된 나노입자 및 사용 방법 Active KR102581296B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488685P 2017-04-21 2017-04-21
US62/488,685 2017-04-21
PCT/US2018/028752 WO2018195526A1 (en) 2017-04-21 2018-04-21 Membrane lipid coated nanoparticles and method of use

Publications (2)

Publication Number Publication Date
KR20190137906A KR20190137906A (ko) 2019-12-11
KR102581296B1 true KR102581296B1 (ko) 2023-09-22

Family

ID=63857020

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197034265A Active KR102581296B1 (ko) 2017-04-21 2018-04-21 막 지질 코팅된 나노입자 및 사용 방법

Country Status (6)

Country Link
US (1) US11413252B2 (cg-RX-API-DMAC7.html)
EP (1) EP3612169A4 (cg-RX-API-DMAC7.html)
JP (1) JP7329839B2 (cg-RX-API-DMAC7.html)
KR (1) KR102581296B1 (cg-RX-API-DMAC7.html)
CN (2) CN110621306A (cg-RX-API-DMAC7.html)
WO (1) WO2018195526A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
WO2021011826A1 (en) 2019-07-16 2021-01-21 Coastar Therapeutics Inc. Process of making membrane lipid coated nanoparticles
CN110638784A (zh) * 2019-09-27 2020-01-03 兆科(广州)肿瘤药物有限公司 一种载有溶瘤病毒的载药微球及其制备方法
EP4093458A4 (en) * 2020-01-20 2024-01-17 Arytha Biosciences LLC Devices containing cellular membrane and uses thereof
WO2023113550A1 (ko) * 2021-12-16 2023-06-22 주식회사 포투가바이오 수지상세포 모방 기능성 나노구조체 및 이의 제조방법
CN117379389B (zh) * 2022-07-12 2026-03-06 四川大学 血小板-溶瘤病毒复合物、其制备方法及其应用
CN115252582B (zh) * 2022-08-19 2024-01-02 复旦大学 红细胞膜杂合pH脂质体包被溶瘤病毒制剂的制备及应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525992A (ja) 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
WO2006090816A1 (ja) 2005-02-25 2006-08-31 Mie University リポソームワクチンの作製法
US20100203024A1 (en) 2006-05-30 2010-08-12 Terman David S Sickled Erythrocytes, Nucleated Precursors & Erythroleukemia Cells for Targeted Delivery of Oncolytic Viruses, Anti-tumor Proteins, Plasmids, Toxins, Hemolysins & Chemotherapy
WO2013052167A2 (en) * 2011-06-02 2013-04-11 The Regents Of The University Of California Membrane encapsulated nanoparticles and method of use
WO2014172685A1 (en) * 2013-04-18 2014-10-23 The Regents Of The University Of California Nanoscale coatings for encapsulation of biological entities
US20150284691A1 (en) 2012-10-29 2015-10-08 The Regents Of The University Of California Composition of viral vectors in lecithin liposomes, preparation method and treatment methods
US20160317591A1 (en) 2013-03-13 2016-11-03 Karen S. Aboody Tropic cell based virotherapy for the treatment of cancer
WO2016192451A1 (zh) 2015-05-29 2016-12-08 湖北盛齐安生物科技有限公司 一种溶瘤病毒制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2158995A (en) * 1994-03-15 1995-10-03 Medical College Of Pennsylvania And Hahnemann University Compositions and methods for vaccines comprising alpha-galactosyl epitopes
US20140350087A9 (en) * 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US20140335115A1 (en) * 2013-05-07 2014-11-13 Oregon Health & Science University Suppressors of mature t cells
CN106794141B (zh) * 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
US11224577B2 (en) 2015-06-19 2022-01-18 The Regents Of The University Of California Treating infection by a platelet-targeting microbe using nanoparticles

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525992A (ja) 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
WO2006090816A1 (ja) 2005-02-25 2006-08-31 Mie University リポソームワクチンの作製法
US20100203024A1 (en) 2006-05-30 2010-08-12 Terman David S Sickled Erythrocytes, Nucleated Precursors & Erythroleukemia Cells for Targeted Delivery of Oncolytic Viruses, Anti-tumor Proteins, Plasmids, Toxins, Hemolysins & Chemotherapy
WO2013052167A2 (en) * 2011-06-02 2013-04-11 The Regents Of The University Of California Membrane encapsulated nanoparticles and method of use
US20150284691A1 (en) 2012-10-29 2015-10-08 The Regents Of The University Of California Composition of viral vectors in lecithin liposomes, preparation method and treatment methods
US20160317591A1 (en) 2013-03-13 2016-11-03 Karen S. Aboody Tropic cell based virotherapy for the treatment of cancer
WO2014172685A1 (en) * 2013-04-18 2014-10-23 The Regents Of The University Of California Nanoscale coatings for encapsulation of biological entities
US20160067191A1 (en) 2013-04-18 2016-03-10 The Regents Of The University Of California Nanoscale coatings for encapsulation of biological entities
WO2016192451A1 (zh) 2015-05-29 2016-12-08 湖北盛齐安生物科技有限公司 一种溶瘤病毒制剂及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of the National Cancer Institute 106(6):1-9(2014.05.16.)
Molecular Cancer Therapeutics 5(3):755-766(2006.03.01.)

Also Published As

Publication number Publication date
CN110621306A (zh) 2019-12-27
US11413252B2 (en) 2022-08-16
JP2020519241A (ja) 2020-07-02
US20200060979A1 (en) 2020-02-27
WO2018195526A1 (en) 2018-10-25
EP3612169A1 (en) 2020-02-26
KR20190137906A (ko) 2019-12-11
CN121154578A (zh) 2025-12-19
EP3612169A4 (en) 2020-09-09
JP7329839B2 (ja) 2023-08-21

Similar Documents

Publication Publication Date Title
US11413252B2 (en) Membrane lipid coated viral nanoparticles and method of use
Feng et al. Plant‐derived vesicle‐like nanoparticles as promising biotherapeutic tools: present and future
Du et al. Extracellular vesicles: a rising star for therapeutics and drug delivery
Chen et al. Surface mineralization of engineered bacterial outer membrane vesicles to enhance tumor photothermal/immunotherapy
CN114206360B (zh) 含有细胞膜的纳米颗粒及其用途
Guo et al. Opportunities and challenges of bacterial extracellular vesicles in regenerative medicine
US20210093580A1 (en) Nanoscale coatings for encapsulation of biological entities
Cheng et al. Nanomedicines for Alzheimer's disease: therapies based on pathological mechanisms
Iscaro et al. Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus
Peng et al. Hybrid cell membrane‐based nanoplatforms for enhanced immunotherapy against cancer and infectious diseases
US12599574B2 (en) Process of making membrane lipid coated nanoparticles
US20220347110A1 (en) Membrane lipid coated nanoparticles and method of use
Ciferri et al. Standardized method to functionalize plasma-extracellular vesicles via copper-free click chemistry for targeted drug delivery strategies
Tang et al. Engineered extracellular vesicles: an emerging nanomedicine therapeutic platform
Tian et al. Platelets camouflaged nanovehicle improved bladder cancer immunotherapy by triggering pyroptosis
TWI651092B (zh) 類血小板蛋白微粒及利用類血小板蛋白微粒傳遞藥物之方法
Zhu et al. Enhancing TIM-3 immunotherapy with epirubicin-loaded pH sensitive fusion membrane nanoparticles for effective glioblastoma treatment
Wang et al. Molecular targeting of intracellular bacteria by homotypic recognizing nanovesicles for infected pneumonia treatment
CN117797274A (zh) 一种三位一体协同治疗脑胶质瘤的同源仿生纳米粒及其制备方法和应用
Lu et al. Inflammation-targeting and self-limited neutrophilic membrane-encapsulated teicoplanin for the treatment of infectious pneumonia
US20240325314A1 (en) Membrane lipid coated nanoparticles and method of use
KR20170104024A (ko) 헬리코박터파일로리균 유래 나노소포 및 이의 용도
Moradi et al. Unlocking the potential of exosomes: overcoming challenges in retention time, stability and targeting
US11617723B2 (en) Composition for hepatic arterial chemoembolization using human serum albumin nanoparticles carrying anticancer agent, and method for producing same
Li et al. Alveolar surfactant-mimicking inhaled biomimetic nanovaccine with alveolar macrophage-targeting property potentiates anti-mpox immunity

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4